Oxford Vacmedix UK Analysis: $20M Raised
What is Oxford Vacmedix UK?
Oxford Vacmedix UK develops immunotherapies based on recombinant overlapping peptide technology, targeting a wide range of cancers. Their lead product, OVM-200, is currently in Phase 1 clinical trials, showing promising safety and immune response data. The company aims to make these therapies accessible to a broad patient population.
Location
The Magdalen Centre, Oxford Science Park, Oxford, England OX4 4GA, United Kingdom
Employees
1-10
Founded
2012
Product Features & Capabilities
- OVM-200
- OVM-100
- OVM-400
- AMR Diagnostic
Use Cases
Treat advanced non-small cell lung cancer; Treat ovarian cancer; Treat prostate cancer; Develop mRNA delivery systems; Conduct Phase 1 and Phase 2 clinical trials
How much Oxford Vacmedix UK raised
Funding - $20M
HQ Full Address
The Magdalen Centre, Oxford Science Park, Oxford, England OX4 4GA, United Kingdom
Other Considerations
Seeking Series B investment for clinical trials; Ongoing Phase 1 trial with strong preliminary data; Spinout from the University of Oxford
See something that needs updating? Suggest edits to this profile.